Literature DB >> 20400977

Array-based genomic resequencing of human leukemia.

Y Yamashita1, J Yuan, I Suetake, H Suzuki, Y Ishikawa, Y L Choi, T Ueno, M Soda, T Hamada, H Haruta, S Takada, Y Miyazaki, H Kiyoi, E Ito, T Naoe, M Tomonaga, M Toyota, S Tajima, A Iwama, H Mano.   

Abstract

To identify oncogenes in leukemias, we performed large-scale resequencing of the leukemia genome using DNA sequence arrays that determine approximately 9 Mbp of sequence corresponding to the exons or exon-intron boundaries of 5648 protein-coding genes. Hybridization of genomic DNA from CD34-positive blasts of acute myeloid leukemia (n=19) or myeloproliferative disorder (n=1) with the arrays identified 9148 nonsynonymous nucleotide changes. Subsequent analysis showed that most of these changes were also present in the genomic DNA of the paired controls, with 11 somatic changes identified only in the leukemic blasts. One of these latter changes results in a Met-to-Ile substitution at amino-acid position 511 of Janus kinase 3 (JAK3), and the JAK3(M511I) protein exhibited transforming potential both in vitro and in vivo. Further screening for JAK3 mutations showed novel and known transforming changes in a total of 9 out of 286 cases of leukemia. Our experiments also showed a somatic change responsible for an Arg-to-His substitution at amino-acid position 882 of DNA methyltransferase 3A, which resulted in a loss of DNA methylation activity of >50%. Our data have thus shown a unique profile of gene mutations in human leukemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20400977     DOI: 10.1038/onc.2010.117

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  113 in total

1.  DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.

Authors:  O Abdel-Wahab; A Pardanani; R Rampal; T L Lasho; R L Levine; A Tefferi
Journal:  Leukemia       Date:  2011-04-26       Impact factor: 11.528

Review 2.  Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.

Authors:  Su-Jiang Zhang; Omar Abdel-Wahab
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 3.  A decade of exploring the cancer epigenome - biological and translational implications.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

4.  Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia.

Authors:  Isabella Fried; Claudia Bodner; Monika M Pichler; Karin Lind; Christine Beham-Schmid; Franz Quehenberger; Wolfgang R Sperr; Werner Linkesch; Heinz Sill; Albert Wölfler
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

5.  Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.

Authors:  F Ostronoff; M Othus; P A Ho; M Kutny; D E Geraghty; S H Petersdorf; J E Godwin; C L Willman; J P Radich; F R Appelbaum; D L Stirewalt; S Meshinchi
Journal:  Leukemia       Date:  2012-06-22       Impact factor: 11.528

6.  Untargeted adductomics of newborn dried blood spots identifies modifications to human serum albumin associated with childhood leukemia.

Authors:  Yukiko Yano; Courtney Schiffman; Hasmik Grigoryan; Josie Hayes; William Edmands; Lauren Petrick; Todd Whitehead; Catherine Metayer; Sandrine Dudoit; Stephen Rappaport
Journal:  Leuk Res       Date:  2019-11-06       Impact factor: 3.156

7.  Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.

Authors:  D Bellanger; V Jacquemin; M Chopin; G Pierron; O A Bernard; J Ghysdael; M-H Stern
Journal:  Leukemia       Date:  2013-09-19       Impact factor: 11.528

Review 8.  Epigenetic alterations in hematopoietic malignancies.

Authors:  Young Rock Chung; Emma Schatoff; Omar Abdel-Wahab
Journal:  Int J Hematol       Date:  2012-09-27       Impact factor: 2.490

9.  The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.

Authors:  David A Russler-Germain; David H Spencer; Margaret A Young; Tamara L Lamprecht; Christopher A Miller; Robert Fulton; Matthew R Meyer; Petra Erdmann-Gilmore; R Reid Townsend; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

Review 10.  Epigenetic Determinants of Cancer.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-09-01       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.